Evidence map›Paper›PMID 20952583›Full record

ArticleCirculation. Heart failure2011

Metformin use and mortality in ambulatory patients with diabetes and heart failure.

David Aguilar, Wenyaw Chan, Biykem Bozkurt, Kumudha Ramasubbu, Anita Deswal

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation. Heart failure, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 8 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 8 syntheses or guidelines pooled it, 199 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Influence of Metformin Discontinuation on Readmission Rate in Patients With Acute Heart Failure.Journal of community hospital internal medicine perspectives · 2024
    Article
  18. Observational
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

David AguilarWinters Center for Heart Failure Research and Section of Cardiology, Department of Medicine, Baylor College of Medicine, 1709 Dryden Street, Houston, TX 77030, USA. daguilar@bcm.edu
Wenyaw Chan
Biykem Bozkurt
Kumudha Ramasubbu
Anita Deswal
The University of Texas Health Science Center at Houston · USMichael E. DeBakey VA Medical Center · US

Funding

NHLBI NIH HHS 5K01-HL092585-02NHLBI NIH HHS K01 HL092585
6 · The paper itself

Abstract

backgroundDespite the common coexistence of diabetes and heart failure (HF), the optimal medial treatment of diabetes in HF patients has not been well studied. We sought to compare the association between metformin use and clinical outcomes in a cohort of ambulatory patients with diabetes and established HF. METHODS AND

resultsUsing propensity score-matched samples, we examined the association between metformin use and the risk of death or risk of hospitalization in a national cohort of 6185 patients with HF and diabetes treated in ambulatory clinics at Veteran Affairs medical centers. In this cohort, 1561 (25.2%) patients were treated with metformin. At 2 years of follow-up, death occurred in 246 (15.8%) patients receiving metformin and in 1177 (25.5%) patients not receiving metformin (P<0.001). In the propensity score-matched analysis (n=2874), death occurred in 232 (16.1%) patients receiving metformin compared with 285 (19.8%) patients not receiving metformin (hazard ratio, 0.76; 95% confidence interval, 0.63 to 0.92; P<0.01). In propensity score-matched analyses, HF hospitalization or total hospitalization rates were not significantly different between individuals treated with metformin compared with those not treated with metformin (hazard ratio, 0.93; 95% confidence interval, 0.74 to 1.18; and hazard ratio, 0.94; 95% confidence interval, 0.83 to 1.07, respectively).

conclusionsMetformin therapy was associated with lower rates of mortality in ambulatory patients with diabetes and HF. Future prospective studies are necessary to define the optimal therapy for diabetic patients with HF.

Indexed as

AgedCohort StudiesComorbidityDiabetes MellitusFemaleFollow-Up StudiesHeart FailureHumansHypoglycemic AgentsMaleMetforminMiddle AgedRetrospective StudiesSurvival RateTreatment OutcomeHypoglycemic AgentsMetformin

Identifiers

PMID20952583
PMCPMC3046634
OpenAlexW2049022861

What Socratic holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.